Zosano Pharma Corporation (ZSAN) News
Filter ZSAN News Items
ZSAN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZSAN News Highlights
- ZSAN's 30 day story count now stands at 4.
- Over the past 26 days, the trend for ZSAN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG are the most mentioned tickers in articles about ZSAN.
Latest ZSAN News From Around the Web
Below are the latest news stories about Zosano Pharma Corp that investors may wish to consider to help them evaluate ZSAN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWith the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday! |
FDA Rejects Zosano Pharma's Application For Zolmitriptan Microneedle System Again, Shares PlungeThe FDA has issued a response letter to Zosano Pharma Corp (NASDAQ: ZSAN) regarding its resubmission of the 505(b)(2) New Drug Application for M207 (zolmitriptan microneedle system). The response letter stated that the FDA did not consider the resubmitted M207 application a complete response to the deficiencies identified in the FDA’s October 2020 Complete Response Letter. The FDA will not begin a substantive review of the application until a complete response is received. The FDA’s response let |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and WarrantsFREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years f |
Zosano Pharma Announces Proposed Public Offering of Common Stock and WarrantsFREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actu |
Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ...Investment company Morgan Jess S & Co Inc (Current Portfolio) buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Microsoft Corp, Vanguard Total International Stock, sells Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Morgan Jess S & Co Inc. |
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms. The measurements of the vaccine should have been 10μg and 15μg, not 10 g and 15 g as previously stated. The corrected release follows: Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today |
Zosano Pharma Announces Publication Of Early Data On Influenza VaccineZosano Pharma Corporation (NASDAQ: ZSAN) announced the publication of Phase 1 trial data of influenza vaccine in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels and was generally well tolerated. The Company noted that a lower dose of an influenza vaccine produced antibody levels similar to an intramuscular injection of the same vaccine at a higher dose. The |
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System” in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent i |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back to a new year, investor! |